Positive Top-Line Results in FSGS Phase 2a Clinical Study
Filed with ASX · · 5 pages · English
In the deck
Story so far
Earlier from Dimerix
- Last Patient Completes Dosing in DKD Phase 2 Clinical Study
- Dimerix Completes $5.8m Placement
- Last Patient Completes Dosing in FSGS Phase 2 Clinical Study
- Global REMAP-CAP Platform Trial Protocol To Include DMX-200
- R&D Tax Incentive Facility
Later from Dimerix
- Dimerix Awarded $1 Million MRFF Funding
- Positive Top-Line Results in DKD Phase 2 Clinical Study
- DMX-700 Data Demonstrates Effect on Key COPD Receptors
- Receipt of R&D Tax Incentive
- Positive Additional Data to Support DMX-200 Development
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix